Plain-English translation of NCT04473781 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a treatment called interstitial brachytherapy for kidney cancer — a way to deliver radiation directly into a tumor using tiny seeds placed through the skin. The treatment is designed for people with early-stage kidney cancer who cannot or do not want to have surgery to remove the kidney.
Some patients with kidney cancer are not candidates for surgery due to health concerns or personal choice, and standard radiation treatments may not work well for kidney tumors. This trial is exploring whether placing radiation directly into the tumor could be a safe and effective alternative option.
You would receive one or two sessions of interstitial brachytherapy, where a needle is placed through your skin into the kidney tumor under imaging guidance, and tiny radiation seeds are delivered directly to the tumor. The sessions may happen on the same day or over two weeks. After treatment, you would have follow-up visits every three months for at least three years, including imaging scans and blood tests to monitor how well the treatment worked and check for any side effects.
AI-generated summary from trial data · Aug 20, 2026 · Not medical advice
United States